No effect of bone morphogenetic protein-7 (OP-1) on the incorporation of impacted bone grafts in a realistic acetabular model.
Bone morphogenetic proteins (BMPs) accelerate bone repair in experimental and clinical conditions. Impacted Morsellized Cancellous Bone grafts (MCB) are successfully used to reconstruct bone defects after failed hip implants. The main question in this study was if BMP-7 (OP-1) mixed with MCB could accelerate the incorporation of MCB and prevents the formation of a soft tissue interface after remodeling of the MCB. A large loaded defect in the acetabulum of goats was reconstructed with a wire mesh and with MCB or MCB mixed with OP-1. After 6 weeks, no differences were found in the revascularization process, in the number of osteoclasts resorbing the MCB, and in the thickness and appearance of the fibrous interface between MCB with or without OP-1. After 6 weeks, enchondral bone had formed in the bone graft layer and on the periosteal anterior and superior rim in the OP-1 group only. More periosteal bone and more bone in the holes of the mesh had been formed in most OP-1 goats. Most MCB was replaced by new lamellar bone after 15 weeks in both groups. We speculate that during or directly after impaction most of the OP-1 is released from the carrier inducing an early effect outside the reconstructive layer at the periosteal side of the acetabulum. Probably most OP-1 has left the reconstruction by the time new vessels and progenitors reached the bone graft. These results do not support the use of OP-1 in impaction bone grafting in patients.
Buma
Pieter
P
Department of Orthopedics, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. P.Buma@orthop.umcn.nl
Arts
J J Chris
JJ
Gardeniers
Jean W M
JW
Verdonschot
Nico
N
Schreurs
B Willem
BW
D000077:Acetabulum / Q000033:anatomy & histology / Q000254:growth & development / Q000502:physiology*; D000818:Animals; D001843:Bone Cements; D001846:Bone Development / Q000187:drug effects; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D016723:Bone Remodeling / Q000187:drug effects; D001862:Bone Resorption / Q000473:pathology; D016025:Bone Transplantation; D005260:Female; D006041:Goats; D008954:Models, Biological; D054457:Tissue Scaffolds; D016212:Transforming Growth Factor beta / Q000494:pharmacology*; D019737:Transplants
D001843:Bone Cements; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D016212:Transforming Growth Factor beta